Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc. announced an extension of the outside date for its previously disclosed $24.0 million private placement of common stock. The original outside date was September 29, 2026, and has now been extended to October 16, 2026. The company and the purchasers have entered into notices and consents that allow for the deferral and coordination of the closing until applicable conditions are met, but no later than the extended outside date. The purchase agreement itself remains unchanged and in full force and effect.

Indaptus Therapeutics reported a net loss of $1.79 million for the three months ended June 30, 2026, a significant improvement from $5.23 million in the prior year. For the six months, the net loss was $4.34 million, down from $9.76 million. The company raised approximately $12.0 million through a private placement of common stock in June 2026 and converted all outstanding preferred stock into common shares during the first quarter of 2026. Despite a going concern warning, management believes it has sufficient liquidity to fund operations through June 30, 2027.

Indaptus Therapeutics reported a Q2 2026 net loss of $1.8 million, a significant reduction from $5.2 million in Q2 2025, driven by an 83% decrease in R&D expenses and a 37% decrease in G&A expenses. The company strengthened its balance sheet with a $12.0 million private placement, bringing total liquidity to $11.6 million as of June 30, 2026. Concurrently, Indaptus discontinued further enrollment in its Decoy20 clinical studies and is evaluating strategic alternatives for its programs and broader operations. At its Annual Meeting, stockholders elected three directors, ratified the auditor, and approved the 2026 Equity Incentive Plan.

Indaptus Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders to be held virtually on August 10, 2026. Stockholders will vote on the election of three Class II directors, the ratification of Haskell & White LLP as the independent auditor for fiscal year 2026, and the approval of the 2026 Equity Incentive Plan. The new equity plan proposes an initial reserve of approximately 13.3 million shares and an annual increase provision.

Indaptus Therapeutics, Inc. entered into a Stock Purchase Agreement on June 17, 2026, to sell 20,000,000 shares of its common stock at $0.60 per share in a private placement. This transaction generated approximately $12,000,000 in gross proceeds for the company. The shares were sold to certain non-U.S. accredited investors, and the company is required to file a registration statement for the resale of these shares within 90 days.

Indaptus Therapeutics announced the resignations of two directors, Mr. David E. Lazar and Mr. Avraham Ben-Tzvi, from all directorship positions, effective June 5, 2026. Additionally, Mr. Walt A. Linscott, Esq. resigned as Chief Operating Officer, effective June 1, 2026, but will transition to a consulting role for the Company. The Company stated that these resignations were not due to any disagreements regarding its operations, policies, or practices.

Indaptus Therapeutics reported a net loss of $2.54 million for the first quarter of 2026, an improvement from a $4.53 million loss in the prior year. However, the company's cash and cash equivalents significantly declined to $1.50 million, leading to substantial doubt about its ability to continue as a going concern. Indaptus is actively exploring strategic transactions, including investments or acquisitions, to create future growth opportunities and secure additional capital.

Indaptus Therapeutics reported Q1 2026 financial results, showing a reduced net loss of $2.5 million compared to $4.5 million in Q1 2025, driven by decreased R&D and G&A expenses. However, the company's cash and cash equivalents significantly declined to $1.5 million from $8.5 million at the end of 2025, with net cash used in operating activities increasing to $7.0 million. Following executive management changes, the company is undergoing a strategic review of its development programs and acknowledges the critical need to raise additional capital.

Indaptus Therapeutics reported a net loss of $2.5 million, or $0.23 per share, for the first quarter ended March 31, 2026, an improvement from a $4.5 million net loss in the prior year. The company saw reduced R&D and G&A expenses. However, cash and cash equivalents significantly declined to $1.5 million, and the company stated it needs to raise additional capital. Indaptus is also undergoing an executive management transition and a strategic review of its development programs and resource allocation.

Indaptus Therapeutics, Inc. announced the appointment of Mr. Tim Ruan and Dr. Johnny Fox Arrowsmith as independent directors to its Board, effective April 22, 2026. Mr. Ruan, 40, brings significant experience as CFO of Ocumension Therapeutics and from senior roles at Goldman Sachs and Morgan Stanley. This filing is an amendment to clarify that Dr. Arrowsmith's legal name is Johnny Fox Arrowsmith, though he uses Yi Zhang professionally.